Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.61 |
| ▸ | YAP1 | P46937 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26668550 | 0.94 | KDM4E (0.56) | KDM4EPKMGPR119YAP1RAB9A | |
| SCHEMBL13930883 | 0.89 | NPC1 (0.59) | KDM4EPKMGPR119YAP1NPC1 | |
| SCHEMBL13930882 | 0.89 | POLB (0.59) | KDM4EPKMGPR119YAP1RAB9A | |
| SCHEMBL29280884 | 0.88 | YAP1 (0.54) | KDM4EPKMGPR119YAP1KEAP1 | |
| SCHEMBL13930884 | 0.88 | LMNA (0.59) | KDM4EPKMGPR119YAP1LMNA | |
| SCHEMBL5777274 | 0.87 | NAMPT (0.61) | KDM4EPKMGPR119YAP1KEAP1 | |
| SCHEMBL7985552 | 0.87 | KDM4E (0.69) | KDM4EPKMGPR119YAP1KEAP1 | |
| SCHEMBL785861 | 0.85 | KDM4E (0.60) | KDM4EPKMGPR119YAP1KEAP1 | |
| SCHEMBL12804554 | 0.84 | NPSR1 (0.68) | KDM4EPKMGPR119KEAP1NFE2L2 | |
| SCHEMBL4914886 | 0.84 | GPR119 (0.53) | KDM4EPKMGPR119YAP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| EP-1802602-A1 | SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006036527-A1 | SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069123-A1 | Substituted dipiperidine CCR2 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069123-A1 | Substituted dipiperidine CCR2 antagonists | CCR2, CCR1, CCR5 | KDM4E 4452/4885PKM 3016/4885GPR119 155/4885 |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | KDM4E 1506/4885PKM 759/4885GPR119 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.